Vera Therapeutics (VERA) EBITDA (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of EBITDA data on file, last reported at -$125.1 million in Q1 2026.

• Quarterly EBITDA fell 118.79% year-over-year to -$125.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$383.4 million (down 98.4% YoY) and the FY2025 annual result came in at -$315.5 million, down 88.71% from the prior year.
• EBITDA declined to -$125.1 million in Q1 2026, from -$94.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$15.1 million in Q2 2022 to a low of -$125.1 million in Q1 2026.
• A 5-year average of -$47.1 million and a median of -$33.6 million in 2022 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2022 — EBITDA tumbled 260.92% — and 2023, when it increased 19.51%.
• Tracing VERA's EBITDA over 5 years: stood at -$33.6 million in 2022, then increased by 19.51% to -$27.0 million in 2023, then sank by 80.98% to -$48.9 million in 2024, then plunged by 92.6% to -$94.2 million in 2025, then tumbled by 32.83% to -$125.1 million in 2026.
• The last three EBITDA figures came in at -$125.1 million (Q1 2026), -$94.2 million (Q4 2025), and -$83.9 million (Q3 2025), per Business Quant data.